FDA - Spark Newswire

1 minute read

Histogen Stops HST 001 Development After Trial Failure, Shifts Focus On Programs For Orthopedic Indications

Today, 8:09 AM

Histogen Inc (NASDAQ:HSTO) has decided to suspend the development of the HST 001 program after taking into consideration the results from…

HSTO

1 minute read

Monopar, National University of Singapore Team Up For Preclinical Assessment Of MNPR-202 In Cancer Settings

By Vandana Singh

Today, 8:09 AM

Monopar Therapeutics Inc (NASDAQ:MNPR) collaborates with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs…

MNPR

1 minute read

FDA
News

Novartis Says Its Candidate For Treatment Of Men With Metastatic Castration-Resistant Prostate Cancer Showed Improvements In Overall Survival

By Benzinga Newsdesk

Today, 8:09 AM

-Reuters

NVS

1 minute read

FDA
News

Adicet ClinicalTrials.gov Study Record Detail For Co.’s ‘Long-Term Follow-up Study for Subjects Treated With Adicet Bio T Cell Investigational Products,’ Shows Not Yet Recruiting

By Benzinga Newsdesk

Today, 8:09 AM

https://clinicaltrials.gov/ct2/show/NCT04911478

ACET

3 minute read

FDA
News

Mirum Pharma Highlights Presentation Of Analyses From Clinical Studies Evaluating Maralixibat In Patients With Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis Type 2

By Benzinga Newsdesk

Today, 8:09 AM

- Maralixibat-treated patients achieving serum bile acid control have improved five-year native liver survival; nominated for prestigious Alex Mowat Prize for best oral presentation in hepatology. - Safety data from

MIRM

1 minute read

FDA
News

Zynerba Pharmaceuticals Announces Presentation Of Efficacy, Safety Findings In Children, Adolescents With Autism Spectrum Disorder (ASD) And Related Disorders At 2021 American Society Of Clinical Psychopharmacology Annual Meeting

By Benzinga Newsdesk

Today, 8:09 AM

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster today from 10:00

ZYNE

2 minute read

FDA
News

COMPASS Pathways, Kings College London Publish Cognition Results From COMP360 Psilocybin Study In Healthy Volunteers

By Benzinga Newsdesk

Today, 8:09 AM

COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I

CMPS

2 minute read

FDA
News

PDS Biotechnology Says Expands VERSATILE-002 Study Of PDS0101, KEYTRUDA In Advanced Head And Neck Cancer To Include Patients Who Have Failed Prior Treatment With Checkpoint Inhibitors

By Benzinga Newsdesk

Today, 8:09 AM

PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell

MRK

1 minute read

Edesa Biotech’s EB01 Shows Encouraging Interim Results In Dermatitis Trial

By Vandana Singh

Today, 8:09 AM

Edesa Biotech Inc’s (NASDAQ:EDSA) EB01 has met a key interim study parameter as part of an adaptive Phase 2b trial evaluating EB01 as…

EDSA

1 minute read

VBL Therapeutics Stock Jumps on Adding PFS as Second Independent Primary Endpoint in Ovarian Cancer Gene Therapy Trial

By Vandana Singh

Today, 8:09 AM

VBL Therapeutics Ltd (NASDAQ:VBLT) has amended the primary endpoint in the OVAL Phase 3 registration-enabling study of VB-111 (ofranergene obadenovec) gene therapy for…

VBLT